Abbott Laboratories Dirección

Dirección controles de criterios 3/4

El CEO de Abbott Laboratories' es Robert Ford , nombrado en Oct 2018, tiene una permanencia de 5.5 años. compensación anual total es $23.27M, compuesta por 6.4% salario y 93.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.024% de las acciones de la empresa, por valor de $44.70M. La antigüedad media del equipo directivo y de la junta directiva es de 5 años y 5.2 años, respectivamente.

Información clave

Robert Ford

Chief Executive Officer (CEO)

US$23.3m

Compensación total

Porcentaje del salario del CEO	6.4%
Permanencia del CEO	5.6yrs
Participación del CEO	0.02%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Jan 26

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Dec 28

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Dec 27

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Dec 03

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Nov 29

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Nov 26

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Nov 01

Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Oct 24

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Oct 20

Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience

Sep 29

Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Sep 26

Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income

Sep 17

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Aug 13

Abbott: This Dividend King Is Ready For Takeoff

Jul 31

Abbott Laboratories Q2 2023 Earnings Preview: Expect Incremental Improvement

Jul 17

The Big Trends: New Frontiers in Healthcare

Jul 13

Abbott Laboratories (NYSE:ABT) Is Experiencing Growth In Returns On Capital

Jul 12

Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Jun 25

Abbott Laboratories: Offers Promising Buying Opportunity (Technical Analysis)

Jun 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Robert Ford en comparación con los beneficios de Abbott Laboratories?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Compensación vs. Mercado: La compensación total de Robert($USD23.27M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Robert ha sido consistente con los resultados de la empresa en el último año.

CEO

Robert Ford (49 yo)

5.6yrs

Permanencia

US$23,268,171

Compensación

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Ford	Chairman of the Board	5.6yrs	US$23.27m	0.024% $ 43.7m
Philip Boudreau	CFO & Senior VP of Finance	less than a year	US$3.32m	0.0023% $ 4.1m
Hubert Allen	Executive VP	11.3yrs	US$7.42m	0.011% $ 19.3m
Robert Funck	Executive Vice President of Finance	less than a year	US$8.99m	0.016% $ 28.3m
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	9.7yrs	US$5.93m	0.0072% $ 13.2m
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.3yrs	US$5.50m	0.0035% $ 6.4m
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	sin datos	sin datos
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	sin datos	sin datos
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	sin datos	sin datos
Christopher Scoggins	Senior Vice President of Commercial Operations	1.3yrs	sin datos	sin datos
Mary Moreland	Executive Vice President of Human Resources	4.8yrs	sin datos	0.0059% $ 10.7m
Jared Watkin	Executive Vice President of Diabetes Care	8.9yrs	sin datos	0.0041% $ 7.5m

5.0yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ABT es experimentado (5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Ford	Chairman of the Board	4.5yrs	US$23.27m	0.024% $ 43.7m
Daniel Starks	Independent Director	7.3yrs	US$349.29k	0.39% $ 701.8m
John Stratton	Independent Director	7.3yrs	US$341.96k	0.00020% $ 363.9k
Nancy McKinstry	Lead Independent Director	12.4yrs	US$405.96k	0.00027% $ 491.3k
Michael Roman	Independent Director	3.1yrs	US$337.96k	0% $ 0
Robert Alpern	Independent Director	15.6yrs	US$441.44k	0% $ 0
Michael O'Grady	Independent Director	1.1yrs	US$283.96k	0% $ 0
Michelle Kumbier	Independent Director	5.9yrs	US$331.96k	0.00018% $ 327.5k
Sally Blount	Independent Director	12.4yrs	US$362.60k	0.00015% $ 272.9k
Claire Babineaux-Fontenot	Independent Director	1.7yrs	US$354.96k	0% $ 0
Darren McDew	Independent Director	4.7yrs	US$331.19k	0% $ 0
Patricia Gonzalez	Independent Director	2.8yrs	US$356.96k	0% $ 0

5.3yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de ABT se considera experimentada (5.2 años de antigüedad promedio).

Abbott Laboratories Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Executive Vice President of Finance notifies of intention to sell stock

Insider recently sold US$2.4m worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Insider exercised options and sold US$2.6m worth of stock

Insider notifies of intention to sell stock

Independent Director recently sold US$4.7m worth of stock

Recent updates

Executive Vice President of Finance notifies of intention to sell stock

New minor risk - Insider selling

Insider recently sold US$2.4m worth of stock

First quarter 2024 earnings: EPS exceeds analyst expectations

First quarter 2024 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now

Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly

Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

Fourth quarter dividend of US$0.55 announced

Now 20% overvalued after recent price rise

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon

Insider exercised options and sold US$2.6m worth of stock

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

The King Is Back: Abbott Laboratories' Path To >11% Annual Returns

The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings: EPS exceeds analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories: Another Healthy Dividend Hike From This Dividend King

Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)

Insider notifies of intention to sell stock

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio

Is Abbott Laboratories (NYSE:ABT) Using Too Much Debt?

Abbott Laboratories: One Of The Safest Dividend Growth Stocks On The Market

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold US$4.7m worth of stock

Abbott Labs Vs. Thermo Fisher: Which Is The Better Healthcare Stock?

Independent Director notifies of intention to sell stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Returns At Abbott Laboratories (NYSE:ABT) Are On The Way Up

Abbott: A Diversified Health Care Company With Strong Underlying Growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Now 20% undervalued after recent price drop

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories Triumphs Over Challenges: A Tale Of Resilience

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories' (NYSE:ABT) Intrinsic Value Is Potentially 33% Above Its Share Price

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories: Buy This Fairly Valued Dividend King For Consistently Rising Income

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

Now 20% undervalued after recent price drop

We Think Abbott Laboratories (NYSE:ABT) Can Stay On Top Of Its Debt

Insider notifies of intention to sell stock

Abbott: This Dividend King Is Ready For Takeoff

Independent Director recently sold US$5.7m worth of stock

Independent Director notifies of intention to sell stock

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations